Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 3/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645973 | 1.00 | GCK (0.38) | GCKAKR1C3PTGS2AKR1C2PIK3CD | |
| SCHEMBL2645574 | 0.87 | GCK (0.40) | GCKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2645570 | 0.87 | GCK (0.40) | GCKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1171737 | 0.85 | GCK (0.52) | GCKAKR1C3AKR1C2PIK3CDPIK3CA | |
| SCHEMBL1171734 | 0.85 | GCK (0.52) | GCKAKR1C3AKR1C2PIK3CDPIK3CA | |
| SCHEMBL1171340 | 0.84 | GCK (0.51) | GCKAKR1C3AKR1C2PIK3CDPIK3CA | |
| SCHEMBL1171343 | 0.84 | GCK (0.51) | GCKAKR1C3AKR1C2PIK3CDPIK3CA | |
| SCHEMBL2646411 | 0.83 | CNR2 (0.38) | GCKAKR1C3PIK3CDPIK3CAPIK3CB | |
| SCHEMBL2645515 | 0.83 | CNR2 (0.38) | GCKAKR1C3PIK3CDPIK3CAPIK3CB | |
| SCHEMBL2645519 | 0.83 | CNR2 (0.38) | GCKAKR1C3PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242397-B1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1242397-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | disclosed |